Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Federal Circuit resuscitates Snyder’s heart valve patent
Americas
A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.   16 October 2020
Seventh Circuit urged to review AbbVie antitrust ruling
Pharma
Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.   15 October 2020
Braun unit sued for infringing hospital’s patents for artificial joints
Biotech
A unit belonging to German company Braun has allegedly infringed five patents relating to artificial joints for knee and hip replacements, according to a complaint filed by the Orthopaedic Institute for Children.   13 October 2020
Pharma
Biopharmaceutical company, Moderna, has announced that it will not enforce patents related to its COVID-19 vaccine while the pandemic is ongoing, and that it is prepared to license the patents to others after the pandemic is over.   12 October 2020
Americas
US Customs and Border Protection officers have seized hundreds of thousands of counterfeit facemasks and unapproved COVID-19 related products worth more than $2.5m during the six weeks leading up to October 1.   8 October 2020
Pharma
South Africa and India have asked the World Trade Organization to cede some stipulations governing IP so that treatments to combat COVID-19 can become more widely available, particularly in low-income countries.   8 October 2020
Americas
French microbiologist Emmanuelle Charpentier and US biochemist Jennifer Doudna have achieved scientific history by jointly winning the Nobel Prize in chemistry for their seminal work on gene-editing technology, CRISPR.   8 October 2020
Biotech
Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.   6 October 2020
Americas
A Johnson & Johnson company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.   29 September 2020
Americas
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.   22 September 2020

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.